<DOC>
	<DOCNO>NCT00363415</DOCNO>
	<brief_summary>This study Phase 3 , global , multi-center , open-label study patient extensive-stage small cell lung cancer . Eligible patient randomly assign receive either pemetrexed plus carboplatin etoposide plus carboplatin . It anticipate pemetrexed plus carboplatin offer similar survival benefit compare etoposide plus carboplatin .</brief_summary>
	<brief_title>Study Pemetrexed Carboplatin Compared With Etoposide Carboplatin Treat Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Clinical diagnosis extensive stage small cell lung cancer ( SCLC ) Capable selfcare may unable carry work activity . No prior anticancer therapy SCLC previously participate study involve pemetrexed receive treatment within last 30 day drug receive regulatory approval indication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>